4-HYDROXYIFOSFAMIDE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C7H15Cl2N2O3P
Molecular Weight	277.085
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1CCOP(=O)(NCCCl)N1CCCl

InChI

InChIKey=JHUJMHKRHQPBRG-UHFFFAOYSA-N

InChI=1S/C7H15Cl2N2O3P/c8-2-4-10-15(13)11(5-3-9)7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)

HIDE SMILES / InChI

Molecular Formula	C7H15Cl2N2O3P
Molecular Weight	277.085
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=17464949https://www.ncbi.nlm.nih.gov/pubmed/27413637 | https://www.ncbi.nlm.nih.gov/pubmed/17786181 | https://pubchem.ncbi.nlm.nih.gov/compound/Glufosfamide

Glufosamide (glucosylifosfamide mustars) consists of iphosphoramide mustard conjugated to glucose, and is an alkylating agent (affecting the ability of the cancer cell to multiply by causing breakage of the DNA strands). Glufosamide is considered a targeted chemotherapy with fewer side effects than alternative chemotherapies. Its specific mode of action on normal and pathological cells is still under investigation. Glufosamide was studied for use in several cancers, like pancreatic and prostate cancer, and head and neck squamous cell carcinoma. Multipe clinical trials have been completed or are still ongoing. Most promising results were found when glufosamide was used in combination treatments, rather than alone.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019763s019lbl.pdf	Crosslinking Agent 81

Conditions

Condition	Modality	Targets	Highest Phase	Product
Germ cell testicular cancer 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019763s019lbl.pdf	Primary		Approved 8429	IFEX Approved Use Ifosfamide injection, used in combination with certain other approved antineoplastic agents, is indicated for third line chemotherapy of germ cell testicular cancer. It should be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna. Launch Date 1988

C_max

Value	Dose	Co-administered	Analyte	Population
200 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, oral dose: 1.5 g/m² route of administration: Oral experiment type: SINGLE co-administered:		IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
203 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, intravenous dose: 1.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered:		IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1360 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, oral dose: 1.5 g/m² route of administration: Oral experiment type: SINGLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1520 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, intravenous dose: 1.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.54 mM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8339288	3 g/m² 1 times / day multiple, intravenous dose: 3 g/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, oral dose: 1.5 g/m² route of administration: Oral experiment type: SINGLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1795004	1.5 g/m² single, intravenous dose: 1.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.12 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8339288	3 g/m² 1 times / day multiple, intravenous dose: 3 g/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	IFOSFAMIDE blood	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf			IFOSFAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
18 g/m2 1 times / day multiple, intravenous (total) MTD Dose: 18 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 18 g/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090	unhealthy, 45 n = 6 Health Status: unhealthy Condition: Sarcoma Age Group: 45 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090	DLT: Neutropenia, Infection... Dose limiting toxicities: Neutropenia (grade 4, 83.3%) Infection (severe, 33.3%) Thrombocytopenia (grade 4, 66.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090
2.25 g/m2 1 times / day multiple, intravenous MTD Dose: 2.25 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.25 g/m2, 1 times / day Co-administed with:: doxorubicin, i.v(45 mg/m2) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	unhealthy, 45 n = 3 Health Status: unhealthy Condition: Breast cancer Age Group: 45 Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	DLT: Neutropenia, Febrile neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 66.7%) Febrile neutropenia (grade 5, 33.3%) Thrombocytopenia (grade 4, 66.7%) Anemia (grade 4, 66.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6
1.2 g/m2 1 times / day multiple, intravenous Recommended Dose: 1.2 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.2 g/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Testicular cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1	Disc. AE: Nephrotoxicity, Renal failure... AEs leading to discontinuation/dose reduction: Nephrotoxicity (severe) Renal failure (severe) Cystitis hemorrhagic (severe) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Thrombocytopenia	grade 4, 66.7% DLT	18 g/m2 1 times / day multiple, intravenous (total) MTD Dose: 18 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 18 g/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090	unhealthy, 45 n = 6 Health Status: unhealthy Condition: Sarcoma Age Group: 45 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090
Neutropenia	grade 4, 83.3% DLT	18 g/m2 1 times / day multiple, intravenous (total) MTD Dose: 18 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 18 g/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090	unhealthy, 45 n = 6 Health Status: unhealthy Condition: Sarcoma Age Group: 45 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090
Infection	severe, 33.3% DLT	18 g/m2 1 times / day multiple, intravenous (total) MTD Dose: 18 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 18 g/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090	unhealthy, 45 n = 6 Health Status: unhealthy Condition: Sarcoma Age Group: 45 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10572607 Page: p.1090
Anemia	grade 4, 66.7% DLT	2.25 g/m2 1 times / day multiple, intravenous MTD Dose: 2.25 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.25 g/m2, 1 times / day Co-administed with:: doxorubicin, i.v(45 mg/m2) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	unhealthy, 45 n = 3 Health Status: unhealthy Condition: Breast cancer Age Group: 45 Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6
Neutropenia	grade 4, 66.7% DLT	2.25 g/m2 1 times / day multiple, intravenous MTD Dose: 2.25 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.25 g/m2, 1 times / day Co-administed with:: doxorubicin, i.v(45 mg/m2) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	unhealthy, 45 n = 3 Health Status: unhealthy Condition: Breast cancer Age Group: 45 Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6
Thrombocytopenia	grade 4, 66.7% DLT	2.25 g/m2 1 times / day multiple, intravenous MTD Dose: 2.25 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.25 g/m2, 1 times / day Co-administed with:: doxorubicin, i.v(45 mg/m2) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	unhealthy, 45 n = 3 Health Status: unhealthy Condition: Breast cancer Age Group: 45 Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6
Febrile neutropenia	grade 5, 33.3% DLT, Disc. AE	2.25 g/m2 1 times / day multiple, intravenous MTD Dose: 2.25 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 2.25 g/m2, 1 times / day Co-administed with:: doxorubicin, i.v(45 mg/m2) Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6	unhealthy, 45 n = 3 Health Status: unhealthy Condition: Breast cancer Age Group: 45 Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/11840607 Page: p.6
Cystitis hemorrhagic	severe Disc. AE	1.2 g/m2 1 times / day multiple, intravenous Recommended Dose: 1.2 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.2 g/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Testicular cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1
Nephrotoxicity	severe Disc. AE	1.2 g/m2 1 times / day multiple, intravenous Recommended Dose: 1.2 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.2 g/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Testicular cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1
Renal failure	severe Disc. AE	1.2 g/m2 1 times / day multiple, intravenous Recommended Dose: 1.2 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 1.2 g/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Testicular cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781	substrate 1037

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2B6 664 CYP3A5 395 CYP2B1 12 CYP2C19 991 CYP2A6 543 CYP2C8 693 UGT 192 alcohol dehydrogenase 7 ALDH1 3 P-gp 1537 OCT2 355 OAT1 326 OAT3 339 MRP1 107

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1925	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/9157990/	yes
PXR 46	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/24401834/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 326	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21077648/	no
OAT3 339	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21077648/	no
P-gp 1537	substrate 3367 Sources: https://www.ingentaconnect.com/content/ben/cdth/2006/00000001/00000001/art00008	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25934575/	poor
ALDH1 3	substrate 3367 Sources: https://www.ingentaconnect.com/content/ben/cdth/2006/00000001/00000001/art00008	yes	Aldoifosfamide 3
CYP2A6 543	substrate 3367 Sources: https://www.tandfonline.com/doi/abs/10.3109/03602539709037591?journalCode=idmr20	yes
CYP2B1 12	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10326030/	yes
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25934575/	yes
CYP2C8 693	substrate 3367 Sources: https://www.tandfonline.com/doi/abs/10.3109/03602539709037591?journalCode=idmr20	yes
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15875221/	yes
MRP1 107	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/26541366/	yes
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21077648/	yes
UGT 192	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/20541539/	yes	4-HYDROXYIFOSFAMIDE 3
alcohol dehydrogenase 7	substrate 3367 Sources: https://www.ingentaconnect.com/content/ben/cdth/2006/00000001/00000001/art00008	yes	4-HYDROXYIFOSFAMIDE 3
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019763s020lbl.pdf#page=28 Page: 28.0	yes		no (co-administration study) Comment: Coadministration of ifosfamide with ketoconazole or rifampin did not produce changes inthe pharmacokinetics of the parent or metabolites that may result in an increased benefit of ifosfamidetherapy. (https://pubmed.ncbi.nlm.nih.gov/11503007/) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019763s020lbl.pdf#page=28 Page: 28.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019763s020lbl.pdf#page=28 Page: 28.0	yes		no (co-administration study) Comment: Coadministration of ifosfamide with ketoconazole or rifampin did not produce changes inthe pharmacokinetics of the parent or metabolites that may result in an increased benefit of ifosfamidetherapy. (https://pubmed.ncbi.nlm.nih.gov/11503007/) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019763s020lbl.pdf#page=28 Page: 28.0

PubMed

Title	Date	PubMed
Phase I clinical trial of isophosphamide (NSC-109724).	1975 Jul-Aug	1100226
Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.	2000 Aug	10968388
Two episodes of ifosfamide-related neurotoxicity in the same patient following different schedules and doses of the drug. A case report.	2000 Nov-Dec	11218192
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials.	2001	11340375
The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.	2001	11321501
Malignant mixed mullerian tumor of the ovary: report of four cases.	2001	11321500
Treatment of ruptured undifferentiated sarcoma of the liver in children: a report of two cases and review of the literature.	2001	11294295
Carnitine protects mitochondria and removes toxic acyls from xenobiotics.	2001	11276827
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.	2001	11244325
Thymic malignancies.	2001	11224991
Salvage chemotherapy in relapsed germ cell tumors.	2001 Apr	11374323
[Pigmented villonodular synovitis: apropos of 3 cases].	2001 Apr	11355581
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.	2001 Apr	11330369
Modified dorsalis pedis flap for coverage of a pretibial pressure sore after hip rotationplasty.	2001 Apr	11254426
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.	2001 Apr 1	11283932
The current status of docetaxel for advanced non-small cell lung cancer.	2001 Feb	11340898
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.	2001 Feb	11313669
Chemotherapy agents in transitional cell carcinoma: the old and the new.	2001 Feb	11246730
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.	2001 Feb	11233808
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.	2001 Feb	11232950
Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.	2001 Feb	11216713
Treatment of mandibular malignant fibrous histiocytoma during pregnancy.	2001 Feb	11213995
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].	2001 Feb	11181327
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.	2001 Feb 1	11157476
Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.	2001 Feb 1	11157022
The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT).	2001 Feb-Mar	11165404
[Addisonian crisis as first manifestation of adrenal gland insufficiency in patient diagnosed with lung cancer].	2001 Jan	11387844
Anticancer drug-induced kidney disorders.	2001 Jan	11219485
Malignant rhabdoid tumour of the uterine cervix.	2001 Jan	11212987
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.	2001 Jan	11196267
Diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin chemotherapy: the pharmacologic double crush syndrome.	2001 Jan	11133638
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.	2001 Jan	11125366
Long-term stent implantation in a case of relapsing intrathoracic Ewing-sarcoma.	2001 Jan 15	11233473
Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.	2001 Jan 15	11208843
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.	2001 Jun	11378339
A preclinical model for experimental chemotherapy of human head and neck cancer.	2001 Jun	11351243
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.	2001 Jun 1	11387352
Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.	2001 Mar	11320670
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.	2001 Mar	11320663
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.	2001 Mar	11290867
Intrasellar rhabdomyosarcoma: case report.	2001 Mar	11270561
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine].	2001 Mar	11265407
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.	2001 Mar	11263932
Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report.	2001 Mar	11255730
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.	2001 Mar 1	11230464
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.	2001 Mar 15	11251014
Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,	2001 May	11347833
Haemoperfusion combined with haemodialysis in ifosfamide intoxication.	2001 May	11328936
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.	2001 May	11325482
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.	2001 May 19	11377651

Patents

Sample Use Guides

In Vivo Use Guide

30-min infusion at a dose of 1.2 grams per m2 per day for 5 consecutive days

Route of Administration: Intravenous

In Vitro Use Guide

Human testicular germ cell tumour lines H 12.1 and 2102 EP were treated with ifosfamide at 50 mg kg-1 day-1.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:10:40 GMT 2023` Edited by `admin` on `Sat Dec 16 10:10:40 GMT 2023`
Record UNII	ARX5AJ985I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

4-HYDROXYIFOSFAMIDE

Common Name

English

ASTA-6569

Brand Name

English

NSC-208841

Code

English

2H-1,3,2-OXAZAPHOSPHORIN-4-OL, 3-(2-CHLOROETHYL)-2-((2-CHLOROETHYL)AMINO)TETRAHYDRO-, 2-OXIDE

Systematic Name

English

4-HYDROXYISOPHOSPHAMIDE

Common Name

English

Code System Code Type Description

FDA UNII

ARX5AJ985I